INZY - Inozyme Pharma, Inc. Stock Price, Fair Value and News

$4.00

Market Closed as of 02 Jul 2025, 04:00 pm ET

INZY Stock Valuation Analysis

Valuation

Max Portfolio %

INZY Price Action

INZY RSI Chart

INZY Stock Valuation Analysis

Valuation

Max Portfolio %

INZY Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

INZY Fundamentals

INZY Earnings

INZY Profitability

INZY Investor Care

Revenue & Growth

How Inozyme Pharma, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

CEO	Dr. Douglas A. Treco Ph.D.
WEBSITE	inozyme.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	56